Emerging advanced approaches for diagnosis and inhibition of liver fibrogenesis
Abstract Background Liver fibrosis results from chronic liver injury and is characterized by excessive deposition of extracellular matrix proteins including collagen. It can progress to cirrhosis and liver failure. Main body of the abstract Multiple cellular signaling pathways drive hepatic stellate...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2024-02-01
|
| Series: | The Egyptian Journal of Internal Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s43162-024-00283-y |
| _version_ | 1827326076827729920 |
|---|---|
| author | Tamer A. Addissouky Majeed M. A. Ali Ibrahim El Tantawy El Sayed Yuliang Wang |
| author_facet | Tamer A. Addissouky Majeed M. A. Ali Ibrahim El Tantawy El Sayed Yuliang Wang |
| author_sort | Tamer A. Addissouky |
| collection | DOAJ |
| description | Abstract Background Liver fibrosis results from chronic liver injury and is characterized by excessive deposition of extracellular matrix proteins including collagen. It can progress to cirrhosis and liver failure. Main body of the abstract Multiple cellular signaling pathways drive hepatic stellate cell activation and fibrogenesis. Advances in biomarkers, imaging modalities, and omics platforms enable noninvasive diagnosis and staging of liver fibrosis. Emerging antifibrotic approaches include medications like pirfenidone, obeticholic acid, and monoclonal antibodies targeting pro-fibrotic mediators. Cell therapies using mesenchymal stem cells demonstrate antifibrotic potential through paracrine immunosuppression. Tissue-engineered liver grafts and biomaterial carriers for localized drug delivery are promising technologies. Microfluidic liver-on-a-chip platforms with patient-derived cells provide unprecedented models to study human liver fibrosis and test drug candidates. Short conclusion Significant progress has elucidated mechanisms underlying liver fibrogenesis and uncovered novel therapeutic targets. Ongoing challenges include translating preclinical findings, improving antifibrotic efficacy, and enabling personalized precision medicine approaches. Further research into combinatorial therapies, biomarkers, and tissue engineering technologies will advance the treatment of liver fibrosis from all causes. |
| first_indexed | 2024-03-07T14:39:25Z |
| format | Article |
| id | doaj.art-1123886915d142c59b7ba0717849e41b |
| institution | Directory Open Access Journal |
| issn | 2090-9098 |
| language | English |
| last_indexed | 2024-03-07T14:39:25Z |
| publishDate | 2024-02-01 |
| publisher | SpringerOpen |
| record_format | Article |
| series | The Egyptian Journal of Internal Medicine |
| spelling | doaj.art-1123886915d142c59b7ba0717849e41b2024-03-05T20:25:04ZengSpringerOpenThe Egyptian Journal of Internal Medicine2090-90982024-02-0136111210.1186/s43162-024-00283-yEmerging advanced approaches for diagnosis and inhibition of liver fibrogenesisTamer A. Addissouky0Majeed M. A. Ali1Ibrahim El Tantawy El Sayed2Yuliang Wang3Al-Hadi University CollegeAl-Hadi University CollegeDepartment of Biochemistry, Science Faculty, Menoufia UniversityJoint International Research Laboratory of Metabolic and Developmental Sciences, Key Laboratory of Urban Agriculture (South) Ministry of Agriculture, Plant Biotechnology Research Center, Fudan-SJTU-Nottingham Plant Biotechnology R&D Center, School of Agriculture and Biology, Shanghai Jiao Tong UniversityAbstract Background Liver fibrosis results from chronic liver injury and is characterized by excessive deposition of extracellular matrix proteins including collagen. It can progress to cirrhosis and liver failure. Main body of the abstract Multiple cellular signaling pathways drive hepatic stellate cell activation and fibrogenesis. Advances in biomarkers, imaging modalities, and omics platforms enable noninvasive diagnosis and staging of liver fibrosis. Emerging antifibrotic approaches include medications like pirfenidone, obeticholic acid, and monoclonal antibodies targeting pro-fibrotic mediators. Cell therapies using mesenchymal stem cells demonstrate antifibrotic potential through paracrine immunosuppression. Tissue-engineered liver grafts and biomaterial carriers for localized drug delivery are promising technologies. Microfluidic liver-on-a-chip platforms with patient-derived cells provide unprecedented models to study human liver fibrosis and test drug candidates. Short conclusion Significant progress has elucidated mechanisms underlying liver fibrogenesis and uncovered novel therapeutic targets. Ongoing challenges include translating preclinical findings, improving antifibrotic efficacy, and enabling personalized precision medicine approaches. Further research into combinatorial therapies, biomarkers, and tissue engineering technologies will advance the treatment of liver fibrosis from all causes.https://doi.org/10.1186/s43162-024-00283-yLiver fibrosisAntifibrotic therapeutic targetsInflammatory mediatorsLiver-on-a-chip platformsCell-based therapiesTissue engineering |
| spellingShingle | Tamer A. Addissouky Majeed M. A. Ali Ibrahim El Tantawy El Sayed Yuliang Wang Emerging advanced approaches for diagnosis and inhibition of liver fibrogenesis The Egyptian Journal of Internal Medicine Liver fibrosis Antifibrotic therapeutic targets Inflammatory mediators Liver-on-a-chip platforms Cell-based therapies Tissue engineering |
| title | Emerging advanced approaches for diagnosis and inhibition of liver fibrogenesis |
| title_full | Emerging advanced approaches for diagnosis and inhibition of liver fibrogenesis |
| title_fullStr | Emerging advanced approaches for diagnosis and inhibition of liver fibrogenesis |
| title_full_unstemmed | Emerging advanced approaches for diagnosis and inhibition of liver fibrogenesis |
| title_short | Emerging advanced approaches for diagnosis and inhibition of liver fibrogenesis |
| title_sort | emerging advanced approaches for diagnosis and inhibition of liver fibrogenesis |
| topic | Liver fibrosis Antifibrotic therapeutic targets Inflammatory mediators Liver-on-a-chip platforms Cell-based therapies Tissue engineering |
| url | https://doi.org/10.1186/s43162-024-00283-y |
| work_keys_str_mv | AT tameraaddissouky emergingadvancedapproachesfordiagnosisandinhibitionofliverfibrogenesis AT majeedmaali emergingadvancedapproachesfordiagnosisandinhibitionofliverfibrogenesis AT ibrahimeltantawyelsayed emergingadvancedapproachesfordiagnosisandinhibitionofliverfibrogenesis AT yuliangwang emergingadvancedapproachesfordiagnosisandinhibitionofliverfibrogenesis |